New #JITC article: Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system bit.ly/4aWuD1u Alexander McLellan

New #JITC article: Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma bit.ly/3UmKek4 Christian Blank Professor Richard Scolyer AO Professor Georgina Long AO Michel WJM Wouters

New #JITC article: Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors bit.ly/3vYFcSN

New #JITC position article and guidelines: SITC recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease jitc.bmj.com/content/12/4/e… Jason Luke, MD, FACP Diwakar Davar, M.D. Joshua Brody, MD Greg Goldmacher Howard Kaufman Sherene Loi, MD…

New #JITC case report: Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination bit.ly/44cHgTH

New #JITC article: Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models bit.ly/3QF3wAf

New #JITC article: Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade bit.ly/3UwZtbu

Excited to present Society for Immunotherapy of Cancer guidelines for clinical research on intra-tumoral #immunotherapy . This was a collaborative effort from expert stakeholders across academia & industry. Tremendous potential from pre- to advanced cancer for novel agents.
jitc.bmj.com/content/12/4/e…

New #JITC article: Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy bit.ly/3JvMws4 HUMBERT Olivier

New #JITC article: Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials bit.ly/4aLSwJh Iakov Davydov @[email protected]

New #JITC article: Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis bit.ly/4488Q4k Arjun Arkal Rao KattahLab